Review
Biotechnology & Applied Microbiology
Pawel Robak, Tadeusz Robak
Summary: In recent years, there have been significant advancements in the treatment of chronic lymphocytic leukemia (CLL), including the use of novel targeted drugs and monoclonal antibodies. Combination therapies with different agents have shown high activity in both treatment naive and relapsed/refractory CLL patients. However, more research is needed to determine the optimal sequencing of therapies and selection of upfront treatment options.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Review
Pharmacology & Pharmacy
Aleksandra Golos, Joanna Gora-Tybor, Tadeusz Robak
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Biochemistry & Molecular Biology
Anna Pula, Pawel Robak, Dariusz Jarych, Damian Mikulski, Malgorzata Misiewicz, Izabela Drozdz, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak
Summary: This study aimed to analyze the expression of selected miRNAs in the serum of MM patients treated with bortezomib-based regimens and determine their ability to predict early mortality. Two miRNAs, hsa-miR-328-3p and hsa-miR-409-3p, were significantly downregulated in the early mortality group. Logistic regression analysis showed that the final model, including these miRNAs, age, and R-ISS 3, had high sensitivity and specificity in predicting early mortality.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Tadeusz Robak, Pawel Robak
Summary: This article summarizes recent achievements in the treatment of relapsed and refractory hairy cell leukemia. The growing understanding of HCL biology has led to the development of several new targeted drugs, which have shown promising efficacy in early clinical trials.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Oncology
Talha Munir, Carol Moreno, Carolyn Owen, George Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Osterborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Carsten U. U. Niemann, Arnon P. P. Kater
Summary: In the GLOW study, fixed-duration ibrutinib + venetoclax treatment showed better progression-free survival (PFS) compared to chlorambucil + obinutuzumab in older/comorbid patients with previously untreated CLL. This analysis examines the kinetics of minimal residual disease (MRD) and its predictive value for PFS, which has not been evaluated for ibrutinib + venetoclax treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Tadeusz Robak, Jaroslaw D. Kasprzak, Dorota Jesionek-Kupnicka, Michal Soin, Pawel Robak
LEUKEMIA & LYMPHOMA
(2023)
Editorial Material
Oncology
Tadeusz Robak
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Juergen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Doehner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Doehner
Summary: This phase 3 study compared the efficacy and safety of the hypomethylating agent guadecitabine with other treatment choices in patients with acute myeloid leukemia unfit for intensive induction chemotherapy. The study found no significant difference in complete remission and overall survival between guadecitabine and the alternative treatments.
Article
Pharmacology & Pharmacy
Pawel Robak, Magda Witkowska, Anna Wolska-Washer, Tadeusz Robak
Summary: Orelabrutinib is a promising drug for the treatment of B-cell indolent lymphoid malignancies and autoimmune disorders, with high selectivity, good efficacy, and excellent safety profile.
EXPERT OPINION ON DRUG DISCOVERY
(2023)
Review
Biochemistry & Molecular Biology
Magdalena Witkowska, Agata Majchrzak, Pawel Robak, Anna Wolska-Washer, Tadeusz Robak
Summary: PI3K & delta; inhibitors are novel agents used to treat B-cell malignancies by inhibiting enzymes in the PI3K/AKT/mTOR pathway. Idelalisib is an effective inhibitor for B-cell lymphoid malignancies.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Letter
Oncology
Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S. Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
LEUKEMIA & LYMPHOMA
(2023)
Review
Oncology
Tadeusz Robak, Anna Krawczynska, Barbara Cebula-Obrzut, Marta Urbaniak, Elzbieta Iskierka-Jazdzewska, Pawel Robak
Summary: Differentiation of leukemic cells in CLL is significant, with dissimilarities in morphology, cytogenetics, and immunophenotype. Atypical CLL differs from typical CLL morphologically and immunophenotypically, with more aggressive clinical behavior and worse prognosis. However, there is no standard criteria for differentiating atypical CLL from typical CLL and its clinical significance is still under debate.
Review
Oncology
Ewa Robak, Marcin Braun, Tadeusz Robak
Summary: Leukemia cutis refers to the infiltration of leukemia cells in the skin, with varied clinical appearances. Diagnosis relies on clinical characteristics and histopathologic features. Treatment depends on the specific diagnosis of leukemia and radiotherapy can be used for palliative care.
Article
Oncology
Anna Pula, Tadeusz Robak, Izabela Drozdz, Konrad Stawiski, Aleksander Rycerz, Malgorzata Misiewicz, Pawel Robak
Summary: This study aimed to develop a prognostic model for bortezomib resistance in multiple myeloma (MM) based on miRNA expression profiling. The results showed that upregulated miR-27b-3p and let-7b-5p were associated with bortezomib resistance in previously untreated MM patients. These miRNAs may serve as biomarkers of treatment response in MM.
LEUKEMIA & LYMPHOMA
(2023)
